DCM
KURA icon

Delpha Capital Management’s Kura Oncology KURA Stock Holding History

Delpha Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,479
Closed -$23K – 699
2017
Q4 		$23K Buy
+1,479
New +$21.8K 0.03% 703

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Delpha Capital Management's KURA Position: Q1 2018 in Review

Delpha Capital Management sold out of Kura Oncology (KURA) in Q1 2018, closing a stake of 1,479 shares — an estimated $23K sold.

Delpha Capital Management first reported a position in KURA in Q4 2017 and held it in 1 quarter. The position peaked at $23K in Q4 2017. 98 funds tracked by Wall St. Rank hold KURA as of Q1 2018.

  • Delpha Capital Management reported no remaining Kura Oncology position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 1,479 Kura Oncology shares in Q1 2018, an estimated $23K.
  • Delpha Capital Management first reported a position in Kura Oncology in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Kura Oncology position peaked at $23K in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.